Integrating SAP Process Orchestration with SAP Advanced Event Mesh via JMS and JNDI for Modern Architecture

Barclays analyst Matt Miksic raised the price target for LivaNova (LIVN) to $58.00, a 5.45% increase from the previous target, while maintaining an "Equal-Weight" rating. The updated target suggests a cautiously positive outlook on the stock, but the equal-weight rating indicates a neutral stance compared to the broader market. LivaNova is a medical-device firm focused on cardiopulmonary solutions and neuromodulation devices, with roughly half of its revenue from the US market.

Barclays analyst Matt Miksic has raised the price target for LivaNova (LIVN) to $58.00, a 5.45% increase from the previous target, while maintaining an "Equal-Weight" rating. This update reflects a cautiously positive outlook on the stock, but the neutral rating suggests a stance that is in line with the broader market.

LivaNova, a medical-device firm, focuses on cardiopulmonary solutions and neuromodulation devices, with approximately half of its revenue coming from the U.S. market. The company recently reported impressive second-quarter results for 2025, with earnings per share (EPS) significantly exceeding expectations. The EPS of $1.05 surpassed the forecast of $0.87 by 20.69%, and revenue reached $353 million, outperforming the anticipated $332.21 million [4].

The updated price target is based on an 8.0x EV/EBITDA multiple on Barclays’ projected next-twelve-months EBITDA of $396 million, up from the previous estimate of $385 million. This represents a slight premium to LivaNova’s current multiple of approximately 7.0x and is roughly in line with the stock’s year-to-date multiple of approximately 8.0x [4].

The price target increase reflects Barclays’ upward revision of sales projections by approximately 3% for 2025, aligning with management’s commentary and updated outlook. The firm has also raised its sales projections by approximately 9% on average per year for 2026 and beyond. Additionally, Barclays has adjusted its earnings per share (EPS) estimates, increasing them by approximately 3% for 2025 and by 5-6% on average per year for 2026 and beyond [4].

Despite the strong financial results, LivaNova has not reported any significant mergers or acquisitions in recent updates. The focus remains on the earnings and revenue results as the primary highlights for investors.

References:
[1] https://www.tipranks.com/news/the-fly/livanova-price-target-raised-to-58-from-55-at-barclays-thefly
[2] https://www.investing.com/news/analyst-ratings/barclays-raises-livanova-stock-price-target-to-58-from-55-93CH-4204016